semaglutide

Overview

Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1RA) developed for the treatment of type 2 diabetes and obesity. It is a long-acting analogue of the endogenous incretin hormone GLP-1, engineered with structural modifications — including fatty acid side-chain conjugation and albumin binding — that extend its plasma half-life to approximately one week, enabling once-weekly subcutaneous or once-daily oral dosing. By binding and activating the GLP-1 receptor, semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts centrally on hypothalamic and brainstem circuits to reduce appetite and food intake. These pleiotropic mechanisms collectively produce improvements in glycemic control, body weight, cardiovascular risk factors, and liver metabolic parameters. Semaglutide is approved under the brand names Ozempic (injectable, for type 2 diabetes and cardiovascular risk reduction) and Wegovy (injectable, for chronic weight management), and as Rybelsus (oral tablet, for type 2 diabetes). In 2024–2025, it received regulatory approval as the first GLP-1-based treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-severe fibrosis, further expanding its therapeutic scope.

Mechanistically, semaglutide engages the gut-brain axis through both peripheral and central GLP-1 receptor populations. Peripheral receptors on pancreatic beta cells and enteroendocrine L-cells mediate insulinotropic and satiety signaling, while central nervous system receptors — particularly in the hypothalamus, brainstem, and reward circuitry — modulate dopaminergic pathways, appetite regulation, and reward-related behavior. This broad receptor distribution underpins growing interest in semaglutide beyond metabolic disease, including neurodegenerative conditions, addiction medicine, and cardiovascular protection.

Recent Publications Focus

Below is a summary of the newest research publications targeting semaglutide (sorted by publication date).

Recent investigations have substantially expanded evidence for semaglutide's effectiveness in type 2 diabetes management across diverse real-world populations and clinical contexts. Multiple real-world cohort studies documented semaglutide's impact on glycemic control, weight reduction, and cardiometabolic parameters in patients with type 2 diabetes in Finland, Pakistan, and the United Arab Emirates. Combination approaches have been explored, including semaglutide with basal insulin and cagrilintide (CagriSema) in patients with inadequate glycemic control, semaglutide with glucose-dependent insulinotropic polypeptide (GIP) to enhance glucose regulation, and semaglutide with sodium-glucose cotransporter-2 inhibitors such as canagliflozin for early diabetic kidney disease management. Research on oral semaglutide formulations revealed that individual estimated exposure levels demonstrate distinct relationships with glycemic response, weight loss, and gastrointestinal tolerability, providing insights into inter-individual variability affecting therapeutic outcomes.

Semaglutide's weight-loss efficacy has been systematically compared with other advanced anti-obesity agents through network meta-analysis of tirzepatide, cagrilintide, and their combinations, while real-world effectiveness studies from Germany and the United States documented outcomes in digital weight-loss services and standard clinical practice. These real-world investigations identified lower persistence rates and weight regain following discontinuation compared to clinical trial populations. Semaglutide has been evaluated as adjunctive therapy after metabolic bariatric surgery—including sleeve gastrectomy in patients with class II-III obesity and in populations with suboptimal prior surgical weight loss—as well as in special populations including adolescents with type 1 diabetes complicated by obesity and preconception use regarding gestational diabetes risk.

Evidence for semaglutide's hepatoprotective mechanisms has advanced understanding of its therapeutic action in liver disease. A mechanistic study demonstrated that glucagon-like peptide-1 receptors on intrahepatic sinusoidal endothelial cells mediate semaglutide's weight loss-independent hepatoprotective effects in metabolic dysfunction-associated steatohepatitis, reframing GLP-1-based therapeutic pathways in diseased liver tissue. Cost-effectiveness analyses compared semaglutide with other approved therapies (resmetirom and tirzepatide) in patients with significant fibrosis, informing clinical decision-making. Semaglutide's impact on liver fibrosis has been documented in people with HIV, expanding knowledge of its therapeutic potential in metabolic dysfunction-associated steatotic liver disease.

Research has identified semaglutide's effects on multiple physiological systems beyond glucose and weight control. Mechanistic investigations revealed that semaglutide targets muscle mitochondrial function to regulate glutamine metabolism, with downstream effects on osteoarthritis pathology in preclinical models. When combined with 15-PGDH inhibitors, semaglutide enhanced muscle repair and strength recovery during weight loss without compromising metabolic benefits. Glucagon-like peptide-1 receptor agonists including semaglutide inhibit the initiation of toxic amyloid-beta-42 aggregation, a process central to Alzheimer's disease pathology, suggesting neuroprotective potential. A real-world Swedish cohort assessed cardiovascular outcomes in individuals with obesity and established cardiovascular disease, while additional studies evaluated semaglutide's association with adult-onset seizure risk and perioperative safety in patients with morbid obesity undergoing robotic urologic surgery.

Substantial progress has been made in optimizing semaglutide delivery and understanding real-world implementation barriers. Novel oral formulations employing silk nanoparticles and ionic liquid-based enteric systems demonstrated enhanced bioavailability and maintained peptide bioactivity while navigating gastrointestinal barriers, with a 2.3-fold increase in maximum plasma concentration compared to current oral formulations. Analytical methods using dynamic light scattering and nuclear magnetic resonance spectroscopy characterized semaglutide's oligomerization states in formulation, informing stability and efficacy. A major workshop by the National Institute of Diabetes and Digestive and Kidney Diseases synthesized real-world evidence on GLP-1 receptor agonist effectiveness, identifying critical knowledge gaps regarding optimal treatment pathways, long-term safety across diverse populations, and implementation challenges including variable insurance coverage and medication shortages that impact clinical outcomes and economic burden.

Background PMIDs

[PMID 41997744]
[PMID 42189199]
[PMID 42372277]
[PMID 42372278]
[PMID 42393458]

Method PMIDs

[PMID 41729594]
[PMID 42173109]
[PMID 42213650]
[PMID 42363996]
[PMID 42410329]

Result PMIDs

[PMID 42241337]

Target PMIDs

[PMID 41098140]
[PMID 41344888]
[PMID 41429002]
[PMID 41582648]
[PMID 41729594]
[PMID 41765029]
[PMID 41772149]
[PMID 41816887]
[PMID 41825212]
[PMID 41852165]
[PMID 41864088]
[PMID 41865758]
[PMID 41915442]
[PMID 41951127]
[PMID 41967967]
[PMID 41969210]
[PMID 41973550]
[PMID 41985454]
[PMID 41986942]
[PMID 42009015]
[PMID 42017410]
[PMID 42066004]
[PMID 42097623]
[PMID 42098901]
[PMID 42098911]
[PMID 42103575]
[PMID 42108418]
[PMID 42114520]
[PMID 42131979]
[PMID 42133988]
[PMID 42138385]
[PMID 42161545]
[PMID 42166306]
[PMID 42166309]
[PMID 42170981]
[PMID 42173109]
[PMID 42174244]
[PMID 42186215]
[PMID 42198918]
[PMID 42207966]
[PMID 42210124]
[PMID 42213238]
[PMID 42214559]
[PMID 42216891]
[PMID 42228536]
[PMID 42229580]
[PMID 42251856]
[PMID 42264960]
[PMID 42285042]
[PMID 42286047]
[PMID 42295649]
[PMID 42304551]
[PMID 42305583]
[PMID 42308439]
[PMID 42332016]
[PMID 42348222]
[PMID 42362054]
[PMID 42365987]
[PMID 42372278]
[PMID 42373916]
[PMID 42413474]